New Company Focuses on Flow Chemistry
News May 17, 2007
Two well known Cambridge-based science companies have joined forces to develop a new concept in flow chemistry aimed at bringing this promising synthesis technique within the reach of every laboratory.
CEO Martyn Fordham said “Continuous flow synthesis offers synthetic and process chemists a wide range of benefits, however some current commercial systems are very expensive. Other approaches involve coupling up an assortment of different components, and pose significant system control and monitoring issues.”
“Uniqsis has been formed to develop and manufacture a solution that will offer the required choice of functionality in an integrated, rational system, and at a sensible price. Our aim is to make this exciting technique accessible to every organic synthesis laboratory. We are well along the development process and intend to introduce our first product towards the end of the year,” Fordham continued.
Paul Pergande, Uniqsis Chief Technical Officer and Director of Grant’s Technology Division added “We have assembled a unique team, combining the skills of our expert engineers with those of scientists enlisted from the Pharmaceutical industry who bring with them many years’ experience of continuous flow synthesis. We also enjoy the full participation and expertise of Pharmacore, Asynt’s US based partner company who are a leading custom synthesis provider.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019